globenewswire news

Transactions under Novonesis’ share buyback program

2026-09-28T12:42:57Z

Please read the announcement in PDF

Attachment

2026_19_Share_buyback

Articles

argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline

2026-09-29T12:00:00Z

September 29, 2026, 8:00 AM EST

Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda

2026-09-29T12:00:00Z

LEXINGTON, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range...

Noah Medical’s Galaxy System Enters Commercial Use in Asia with First Procedure Completed in Hong Kong

2026-09-29T12:00:00Z

SAN JOSE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Medical robotics innovator Noah Medical today announced the successful completion of its first commercial procedure in Asia using the Galaxy™ System at...

Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting

2026-09-29T12:00:00Z

NEW YORK and WALTHAM, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of...

Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron

2026-09-29T12:00:00Z

Topline Data from First-in-Human Pharmacokinetic Study Anticipated in the Fourth Quarter of 2026

Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD

2026-09-29T12:00:00Z

FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases, today...

Apyx Medical Announces New Clinical Study Demonstrating Renuvion®’s Impact on Skin Quality

2026-09-29T12:00:00Z

Patients reported high satisfaction and visible improvements in skin elasticity, youthfulness, and radiance

NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease

2026-09-29T12:00:00Z

- SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeable memory or functional symptoms-

DiFusion to Define Therapeutic Biomaterials Category at NASS 2026

2026-09-29T12:00:00Z

Red Theater presentation will distinguish conventional biotolerable implants from materials deliberately engineered to influence the host response and participate in healing

Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)

2026-09-29T12:00:00Z

WATERTOWN, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic” or the “Company”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins...

Claris Bio Announces Oral Presentations at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting and Eyecelerator @ AAO

2026-09-29T12:00:00Z

SAN FRANCISCO, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Claris Biotherapeutics, Inc., a late-stage biopharmaceutical company dedicated to advancing transformative therapies for sight-threatening conditions where limited or no treatment options exist,...

Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development

2026-09-29T12:00:00Z

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates...

Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer

2026-09-29T12:00:00Z

Incidence and prevalence of OPSCC continue to rise in the U.S. largely driven by HPV infection

Beta Bionics to Announce Third Quarter 2026 Financial Results on October 27, 2026

2026-09-29T12:00:00Z

IRVINE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to...

Precision Optics to Participate in the Lytham Partners Fall 2026 Investor Conference

2026-09-29T12:00:00Z

LITTLETON, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, will...

Weight Watchers and Google Health Enterprise Launch New Collaboration to Enhance Engagement and Outcomes in Weight Health Programs

2026-09-29T12:00:00Z

Starting in the employer-sponsored market, eligible Weight Watchers members will gain access to Google Fitbit Air and Google Health Enterprise—connecting daily health behaviors with Weight Watchers' science-backed weight health program

Glass House Brands Announces Planned Retirement of Chief Financial Officer

2026-09-29T11:35:00Z

This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated June 10, 2026, to its short form base shelf prospectus dated June 10,...

Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB

2026-09-29T11:30:00Z

October 20th Meeting with the Division of Neurology Expected to Define Endpoint for Phase 3

Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis

2026-09-29T11:30:00Z

Descartes–08 demonstrated improvement in mean change from baseline in MG-ADL following initial treatment and retreatment; mean MG-ADL reduction of 6.6 points at Month 12 following retreatment

Optimi Health Appoints Melanie Pump to Board of Directors

2026-09-29T11:30:00Z

Seasoned finance executive brings more than 25 years of leadership experience across technology, digital infrastructure, software, fintech and emerging growth companies

Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer

2026-09-29T11:30:00Z

Proposed seamless design would incorporate previously FDA-cleared dose-optimization work into a single registration-intent program aligning it with Company’s capital-efficient development strategy